Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trialJingjing Li, Jieer Ying, Zhe Han et al.|Nature Communications|2025Cited by 12
Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancersJiaojiao Ni, Jieer Ying, Chaoqun Li et al.|BMC Medicine|2025Cited by 7
Phase Ⅱ Study of Combined Sintilimab and Anlotinib with Gemcitabine plus Cisplatin in Advanced Biliary Tract Cancer: Efficacy, Safety and Optimize DoseJingjing Li, Jieer Ying, Shurui Zhou et al.|Research Square|2024Cited by 1
First-line serplulimab and bevacizumab combined with nab-paclitaxel/gemcitabine followed by mFOLFOX in advanced pancreatic cancer: A phase II trial.Jieer Ying, Yunben Yang, Qi Xu et al.|Journal of Clinical Oncology|2025Cited by 1